NCT00075933

ARQ 501 in Subjects With Cancer

A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (planned)
• Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT). ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	ARQ 501

Timeline

• Start date: 2003-09-01
• Primary completion: 2007-01-01
• Completion: 2007-01-01
• First posted: 2004-01-13
• Last updated: 2009-04-28

Locations

2 sites across 1 country: United States